What's GSK's return on marketing?

If you're wondering how GlaxoSmithKline's sales-and-marketing team is doing, we might have the answer. Blogger Jim Edwards looks at GSK's yield on its marketing dollars and finds that they're "just about treading water." The revenue yield and gross profit yield on every dollar the company spent on selling, general, and administrative expenses was flat last quarter, down from 1 percent and 7 percent respectively in the first quarter. "The overall trend seems to be down," Edwards notes. Then he offers some cold comfort: After looking at these numbers for one drugmaker after another, he says, he knows that GSK isn't alone in seeing its marketing ROI lose steam.

- see the post at NRx

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.